Fidelity Investments’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-120,633
| Closed | -$181K | – | 5665 |
|
|
2023
Q1 | $181K | Buy |
120,633
+6,772
| +6% | +$9.12K | ﹤0.01% | 3017 |
|
|
2022
Q4 | $114K | Buy |
113,861
+10,940
| +11% | +$14.7K | ﹤0.01% | 3165 |
|
|
2022
Q3 | $185K | Sell |
102,921
-433
| -0.4% | -$1.25K | ﹤0.01% | 3069 |
|
|
2022
Q2 | $300K | Sell |
103,354
-344
| -0.3% | -$849 | ﹤0.01% | 3013 |
|
|
2022
Q1 | $286K | Buy |
103,698
+103,423
| +37,608% | +$325K | ﹤0.01% | 3158 |
|
|
2021
Q4 | $1K | Sell |
275
-221,360
| -100% | -$1.38M | ﹤0.01% | 4243 |
|
|
2021
Q3 | $1.89M | Sell |
221,635
-203,165
| -48% | -$2.87M | ﹤0.01% | 2578 |
|
|
2021
Q2 | $6.97M | Sell |
424,800
-33,900
| -7% | -$685K | ﹤0.01% | 2232 |
|
|
2021
Q1 | $10.1M | Hold |
458,700
| – | – | ﹤0.01% | 2031 |
|
|
2020
Q4 | $14.2M | Buy |
458,700
+66,200
| +17% | +$1.67M | ﹤0.01% | 1847 |
|
|
2020
Q3 | $7.98M | Buy |
+392,500
| New | +$6.89M | ﹤0.01% | 1903 |
|
|
2019
Q4 | – | Sell |
-78
| Closed | -$1K | – | 4389 |
|
|
2019
Q3 | $1K | Buy |
+78
| New | +$1.22K | ﹤0.01% | 3703 |
|
Fidelity Investments's TCRR Position: Q2 2023 in Review
Fidelity Investments sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 120,633 shares — an estimated $181K sold.
Fidelity Investments first reported a position in TCRR in Q3 2019 and held it in 12 quarters. The position peaked at $14.2M in Q4 2020. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.
- Fidelity Investments reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Fidelity Investments sold 120,633 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $181K.
- Fidelity Investments first reported a position in TCR2 Therapeutics Inc. Common Stock in Q3 2019 and held it in 12 quarters.
- Fidelity Investments's TCR2 Therapeutics Inc. Common Stock position peaked at $14.2M in Q4 2020.
- 0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.
Based on Fidelity Investments's 13F filing for Q2 2023, filed 11 Aug 2023.